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H. Coenraad Hemkerl and Suzette Bdguin
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Introduction
Thrombin is a pivotal player in the intricate scenario that ensurcs
haemostasis when riggered by injury but that leads to thrombosis
when set off inappropriately. Thombin generation is due to a
complex enzymatic mechanism by which, in triggered plasma,
thrombin is first formed and subsequently inactivated- In ivo,
this process is closely intertwined with functions of blood cells
and vessels. Nevertheless, aii circumstances that reduce the
thrombin generating capacity of plasma (e.g. every form of
anticoagulation) have an antithrombotic and haemonhagic effect,
and all conditions that increase thrombin generation (e.g.
deficiencies of antithrombin or the proteins C or S, APC resistance)
foster tlnombosis (see also Fig. 1). Therefore the ttuombin
generating capacity of plasma is one of the main determinans of
haemoslasis and thrombosis. In the managementof anticoagulant
therapy and for the detection of thrombosis and bleeding risks ' we
need a laboratory parameter that expresses this function. Since
more than a century clotting times are used for this purpose, but
they are insensitive to hypercoagulation and barely sensitive to
moderate coagulation defects. Moreover a plasma sample clots
already when only 1G-20 nM of thrombin are formed, at a
moment that the large majori ty (>95Vo) of thrombin has still to be
generated. Consequently, feahres of the thrombin generating
process that take place after clotting has occurred are notreflected
in the clotting time. A classical example is the thromboplastin
time, that is hardly prolonged even if the amount of thrombin
formed is substantially decreased by the presence of heparin (see
Fig. 2). There is a need for a parameter that decreases upon
hypocoagulation of any kind and increases in hypercoagulability'
in proportion to the amount of active thrombin that is fonned
during coagulation in aplasma sample' The limiteddataavailable
at this moment suggest that the ETP, contrary to the PT and the
APT[, is a parameter that derreases upon hlpocoagulation of
any kind and increases in hypercoagulability, in proportion to the
thrombin forming capacity of a plasma sample (1'2).
The potency of thrombin generation of the plasma is not to be
confused with the extent of ongoing thrombin generation in the
body. Fragme nt 1.2 e.g. reflects that tkombin is being generated
in the body. It is a smoke detector that reports an ongoing fire. A
test for hypo- or hypercoagulability however should indicate the
fire risk, i.e. the potential thrombin-forming capacity of the non
triggered system. The difference between the nrro appears e.g. in
DIC (disseminated inravascular coagulation) with consumption
coagulopathy, where the indicators of ongoing coagulation are
high but the capacity of the plasma to generate hrombin is low.
The mechanlsm of thrombln generatlon
In the mechanism of thrombin generation three essentially different
types of action can be recognized, thatcan be represented by three
axis: X) Thrombin production and inactivation in the sfrict sense
of the word, Y) Modulation of the reaction velocity nd Z)
Lncalization at the site of vascular damage. In Fig.l the X and Y
axis are shown, the Z axis is not rendered. These processes
cooperate at the level of single enzyme complexes; e.g.
prothrombin conversion as such is carried out by factor Xa, with
a velocity that is determined by the availability of factor Va and
the process remains confined to the surface of a procoagulant
membrane.
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Fie. l. A scheme of thrombin generation. Lines with open arrow heads:
ctrEmical conversiont lines riith black arrow heads: activation of a
oroenzvme (e.q. Xa .€ Thrombin= factor Xa converts protfuombin into'ttuomUin); 
ltoi"dlines with open arrow heads: activating action; Dotted
lines with black arrow heads: inhibitory action.
The ordinate.Tlte core of the thrombin generation mechanism is
the production inactivation axis. Thrombin is produced by the
well known "cascade" mechanism, i.e. the tissue factor faclor
VIIa complex (TF-VIIa) activates factor X, factor Xa activates
prothrombin (3-5). The resulting thrombin is inactivated by
antithrombin ( N) (47 Vo), ormacroglobulin (o.rl'/)(-147o) and
minor inhibitors (-9Vo).Ttrc production is limited in time by the
tissue factorpathway inhibitor (TFPI): When a sufficient amount
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of factor Xa is formed, the generation of more factor Xa is shut
down because a XaTFPI complex forms that efficiently inhibits
further activity of TFVIIa (6). Factor IX is activatedby the factor
VIIaTF complex like factor X is. Together with factor VItra it
forms an altemative factor X activator that is not inhibited by
TFPI but the activity of which is modulated by factor VIII
activation and inactivation (see below). This reinforcement loop
(the Josso loop) probably constitutes an escape mechanism that,
at low TF, prevents precocious arrest of factor Xa formation via
the TFPI mechanism.
The abscissa. The second axis is modulation of thrombin
generation velocity via activation and inactivation of factor V
and factor VIII. In their activated form these factors enhance the
proteolytic activity of their parhers (F.Xa and F.IXa resp.)
approximately a thousand fold (3-5). The appearance and
disappearance of factor Va (VIIIa) is governed by thrombin.
Activation of factor V in plasma can be inhibited by hirudin, so
factor Xa is not likely to be the physiological activator (l). The
inactivation of factor Va (VtrIa) is also thrombin dependent
because the scavenger of factor Va (VIIIa), activated protein C,
is generated by the thrombomodulin thrombin complex (7,8).
Factor V is probably preferably activated by meizothrombin
at a phospholipid surface (9) whereas factor VIII is kept in
solution by von Willebrand factor and activated by thrombin in
free solution. Meizothrombin is insensitive to the AT enhancing
effectof heparin (10), whichmay explain why the thromboplastin
time is relatively insensitive to heparin. Under the conditions of
the APfi, however, the lag time of thrombin formation is mainly
dependent upon the feedback activation of factor VIII by free
thrombin, and therefore is sensitive to heparin.
The thi rd axi s. Several reactions in thrombin generation (indicated
by boxes in Fig. 1) proceed to a significant extent only when the
reactants arc adsorbed onto aphospholipid membrane that contains
phosphatidylserine (PS). Such membranes occur at sites where
endothelial integrity is lost,so thatthrombin generation isconfined
tolesions in the vasculature. PS is almostexclusively foundat the
cytoplasmatic side of cell membranesandis hardly exposedatthe
exterior of the cell (11). When a vessel is damaged, cell damage
will offer some PS containing membranes to the plasma. TF
meets factor VII and so starts the coagulafion cascade. Moreover
collagen is exposed to which can further cause platelet adhesion
(12). As soon as traces of thrombin are formed, the simultaneous
action of thrombin and collagen induces hansbilayer movement
of PS in the platelet membrane and the platelet surface becomes
procoagulant (l 1).
PS containing membranes enhance the velocity of ttrrombin
generation because clotting factors meet more easily when
adsorbed at these surfaces. Prothrombin, e.g., reaches the
prothrombinase complex by diffusion in the plane of the surface
(13). The apparcnt Km of prothrombin conversion, (i.e. the
concentration of prothrombin in solution that is necessary to half
saturate prothrombinase) decreases proportionally with the size
of the procoagulant surface that is available around a
prothrombinase molecule. Thrombin formation by a
prothrombinase complex on a large procoagulant surface is so
fastthat, underphysiologicalconditions, the velocity of itsaction
is determined by the velocity at which prothrombin can be
delivered to the surface rather than by the capacity of the enzyme
(k*,= 3600 mini, Km= 5 nM, 13).
The thrombin generation mechanism is so replele with posi-
tive and negative feedback mechanisms that its kinetics show a
strongly nonlinear behaviour. On the one hand parameters may
vary without changing the output very much, on the other hand,
small changes in one or more of the constituent activities may
have unexpected, and unexpectedly large, effects on the output
(14,6). Thisprecludes that anyof the isolated functions within the
mechanism will adequately render the function of the whole. In
order to assess the function of the thrombin generation mechanism
one therefore has to measure thrombin, under conditions that are
as near as possible to those in vivo.
The endogenous thrombln potentlal
We can imagine that in an areawhere thrombosis develops, the
number of natural substrate molecules (fibrinogen, membrane
receptors etc) that is cleaved by thrombin, determines the extent
of the thrombotic response. If the thrombin substrale is not
exhausted (which fibrinogen e.g. easily is) then the number of
molecules converted by thrombin is proportional to both the
concenbation of this enzyme and the time that itcan act, i.e. to the
area under the thrombin time curve (Ftg.2).Therefore this area
reflects the amountof (natural) subshate that couldpotentially be
converted by ttre thrombin generated in the sample, also under in
vivo conditions. We called it the endogenous thrombin potential
(ETP) (2). As such it is not new. The area under a thrombin
generation curve has been used by Biggs and Macfarlane (15) to
determine prothrombin, making the prothrombin concentration
the only variable in the system. We, on the contary, use it to
assess the combined effect of all the factors that may influence
thrombin generation in a given sample.
Time (min)
Fig. 2. A thrombin generation curve obtained by subsampling.
I : amidolytic activity on 52238; ! : ttuombin activity; + : oqM-IIa
activity; x: amidolyiic activity in the presence of 0.05 U/ml of
unfr actionated heparin.
After thrombin generation is over and free thrombin has
disappeared we measure a residual amidolytic activity (Fig.2).
This is due to the c,, macroglobulin thrombin complex
(crM-IIa). A simple mathematical procedure allows to split the
experimental curve into the part due to free thrombin and
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the part that is due to this complex (Fig.2, see also below).
How to measure the endogenous thrombln potentlal
The obvious way to determine the ETP is to calculate the area
under the thrombin time curve such as it can be obtained by
subsampling from aclotting plasma sample @g.2). This method
is labourintensive and unsuitable for use in the clinical laboratory.
Another approach is to simply add an artificial thrombin subshate
(e.g. a chromogenic substrate) to the sample and determine the
amount of product hat is converted after the thrombin generation
process is over. If the subshate is not exhausted, then the
concentration of product will be proportional to the amount of
any other @hysiological) subsrate that could potentially be
converted by the thrombin generated in that plasma, i.e. to the
ETP. There are some practical problems though. In the firstplace
none of the conventional thrombin substrates can be used because
any concentration that can be added will be consumed before
thrombin generation is over. Thus we need a substrate that is
cleaved slowly. Yet it has to be specific for thrombin, because, if
it would bind significantly to another clotting enzyme, it would
interfere with the thrombin generatiorr process. Preferably the
subshate should be consumed to a limited exbnt (<lo7o),in order
for the product formed to remain lineady proportional to the
surface under the thrombin generation curve. We found two
substrates that fulfil these conditions (Iable l).
Table 1. Properties of two chromogenic substrates suitable for measuring
the ETP.
Substate Thrombin Factor Xa
Time (min)
Fis. 3. Continuous resistation of the conversion of a slow thrombin
substrate during coafuhtion of plasma. P: Experimental cwve; A:
Subshate conversion due to thrombin activity; B: substrate convenion
dueto orM-IIaactivity. AandB are calculatedfrom P as indicatedinthe
text.
moment therefore is proportional (constant = k) with the time integral of
free thrombin. So B(t) is the integral of A(t) multiplied by k. In practice
the integral can be replaced by the sum of all values of A at that moment
available. It follows that at measuring point n in time, the total amount
of product formed @n) equals the amount converted by free thrombin
(A") plus the arnount of product formed by k.(Ao+A,+......+A*,), so
P, = A" + k (Ao+A,+. ' . . . .+A,-,).  I t  fol lows that An equals
(l -k).A*,+(P"-P*,). In this way the course of An can be calculated from
the experimental data (i.e. the coune of P,) if k is known. This (sample
dependent) constant can be found by trial and error, because, from the
moment on that no free thrombin is left, 4 will not increase further.
Itis easy to write aprogram inwhich atime seriesofP is entered and that
calculates a time series of A with any assumed value of k. That value of
k that renders a steady end level of A in the end phase of the reaction,
when no more free thrombin is generated, is the right value. The steady
end level of A then is proportional to the ttrombin potential by a factor
F [=(Km+Syt".,.S], with S being the substrate concenhation andKm and
\, the kinetic constants of the conversion of the subatrate by thrombin.
The thrombin dependentpartof the curve can also be obtained
directly, after inactivation of c,r-M, either enzymatically or by
reacting its internal S-cysteinyl-g-glutamyl thiolester.
Hydroxylamine, at 100 mM,effectivelydestroys c,rmacroglobulin
activity. As an additional benefit it renders the fibrin clot
translucent, probably because it constitutes a substrate for factor
XIIIa that competes with fibrin and hence prevents the light
scattering thatresults from crosslinking. We still have to determine
if, and to what extent, hydroxylamine interferes with the normal
thrombin generation mechanism. Preliminary results lead us to
suppose that by addition of hydroxylamine the o2M effect can be
abolished, so that the experimental OD.trace takes the form of
curve A in Fig. 3 and the ETP can be determined as a simple
endpoint measuremenl
We adapted the ETP assay in defibrinated plasma to a Cobas
laboratory automaton, which enables us to carry out more than 50
determinations per hour. The ETP in platelet rich plasma is not
readily automated. In such plasma defibrination is impossible
withoutremoving the platelets and the addition of hydroxylamine
may damage the platelet membrane. For the time being the ETP
of a platelet rich sample has to be determined via a
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Km
(mM)
kcat
(s-l)
kcat
(s-1)
Msc-Val-Arg-pNa l24O O.n NH
lvZ-Aib-Arg-pNA 830 0.46 3070
H.D-Phe-Pip-Arg-pNA* 10 -150 35
*A current thrombin substrate, added for comparison.
The fibrin that forms in clotting plasma interferes with direct
spectroscopic observation. This imposes defibrination of the
sample or the addition of substances that render the clot translucent
(see below).
Fig. 3 shows an O.D. trace obtained with one of the substrates
added to clotting defibrinated plasma. After thrombin generation
is over, product formation continues, due !o the c, macroglobulin
thrombin complex (cqM-IIa). Via a similar mathematical proce-
dure as used to obtain the thrombin curve in Fig.2, the O.D.hace
can be dissected into the part that is due to free thrombin and the
part that is the result of the action of the ofi-Ila complex on the
subshate (Fig. 3).
The O-D. signal [P(t)] consists of two parts. One [A(t)] is generated
by the actionof free thrombin on the addedsubstrate andtheother [B(t)]
by qM-IIa action. crrlrtl-tra is formed with a velocity proportional to the
concenhation of free thrombin. The amount of crrM-IIa present at any
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thrombin generation curve obtained by subsampling.
The ETP of normal individuals equals 382 nM'min + 52
(S.D.,n=86) (As the ETP represents asurface on the concentration
time plane, its dimensions are concentration multiplied by time'
i.e. nM.min. The value may vary somewhat between labs,
dependent upon the calibration factor used to convefi OD changes
into concentrations of thrombin. In clinical practice itis convenient
to express the ETP as a Vo of the normal value). The ETP is hardly
dependent upon the concentration of thromboplastin used' We
prefer to measure the ETP after triggering with dilute recombinant
hornan tissue factor because we think this to be nearest to the
physiological situation. Triggering the ETP via the contact
aciivation mechanism is equally well possible Fig'4)-
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Fie. 5. The influence of the level ofvitamin K dependent factors on the
ilP:ih;i";il"Il, X and VII were independently varied between 0 and
tW" ia the influence on the ETP was measured'1: protfrombin;
n : factor X; +: factor VII.
oay
Fie. 6. The course of tluomboplastin-time, anri-factor Xa activity
;e th; ItTP in 
" 
p"ti"nt n""ted f6r ttuombosis' +: ETP; ! : anti-factor
i" *titirv; -i firomboplastin-time. Heparin was,administered from
admission to day 9. oral anticoagulatlon rrom <uly 4 on'
in a lust group of animals (n= 8) the diet decreased the ETP by
over 35Vo (n= 8) with comparison to a control group
(C.Nieuwenhuys, J.W.M. Heemskerk, S.B6guin, unpublished)'
The limiteddata available, show that ETP is increased both in
congenital and in acquired hypercoagulant states. It is increased
Ay IZVI in women using oral contraceptives (21)' In 6 patients
thatwere hospitalizedwittr anactive venous thrombosis, the ETP
was 132 t t6 Vo of tnenormal value, as compared to 109 t 13 in
was not systematically increased ( 16 t l4%o), yetintwo out of 7
patients ii was increasedby 33Vo and4}Vo (K' Faber, S'B6guin'
preliminary results).
We found the ETP to be increased in antithrombin deficiency '
1 0
Time after SC iniection (h)
Fie. 4. The course of the ETP after subcutaneous injection of
on'nactionatea nd low molecular weightheparin. In l2 healthy_volunteers
heparin iniected subcutaneously at t = 0. The mean and S'EM are grven
of'ttr" *ti"uitv of the ETP comiared to the preinjection sample' --
i';0OO-ru 
'"tftactionated 
treiarin; l: 40 mg enoxaparin; + : 75 mg
enoxapann.
The ETP In hypo- and hypercoagulation
Up to this moment there are a number of different observations
that suggest the ETP to be a sensitive indicator of hyper- and
hypocoagulability butvatidation studies are still tobe performed'
ftri Bfp is more sensitive to the effect of both unfractionated-
and low molecular weight heparin than the APTI' A dose
(Frg. 5) (18). Half normal ETP values are observed at about the
following clotting factor concentrations: hothrombin: 507o,
FYII:2Vo;FX: 107o. It is interesting to note that, when switching
from heparin therapy to oral anticoagulation, theETP, unlike PT'
APTT and anti-factor Xa activity seems to render the level of tJrc
mixed heatment (Fig. 6) (19). To our surprise the ETP, when
measured in whole blood, decreased under the influence of
aspirin (20). In an ongoing study, rats are being tested for the
influence of a fish oil containing diet on the ETP. It was found that
0 1 2 3 4 5 5 7 8 9 t 0 1 t
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It can be seen fromref . 22 that in presence of thmmbomodulin the
ETP of normal plasma decreases more than that of patients with
a protein S or a protein C deficiency. It also has been observed that
APC resiscance is readily detected by determining the effect of
APC on ttre ETP (GAF Nicolaes, G Tans, J Rosing, unpublished
results).
ur-M Q-3 mM) is present in excess over thrombin (< 0.3
mM) during the whole of the thrombin generation process.
Therefore the amount of orM-IIa formed after coagulation is
proportional to the ETP as long as the same plasma is studied.
This can be used to estimate the influence on the ETP of
modifying additions such as thrombomodulin (to search for
protein C and S deficiency and APC resistance), APC (fer APC
resistance) or to investigate the influence of in uitro addition of
anticoagulants (2).
Summary
Thrombin generationis apivotal functionofplasmain haemostasis
and thrombosis. Its mechanism isessentially the classical cascade,
the velocity of which is governed by the availability of factors Va
and VIIIa and that is confined to the surface of the procoagulant
membranes which appear at the site of"injury.
There is no routine testthatqqntitatively renders the thrombin
forming capacity of a plasma sample. Clotting times (PT-
prothrombin time, APTT-activated partial romboplastin time)
do not reflect ths sysl all thrombin generation and are insensitive
to hypercoagulative states. The endogenous thrombin potential
@TP), i.e. the area under the thrombin'generation curve, better
represents his function.
We developed a method to assess the ETP in the routine
laboratory. The first results,suggest that it is a sensitive indicator
for every form of anticoagulation. It is increased in
hypercoagulable states thus far sfudied, both congenital and
acquired and can be designed to indicate deficiencies in protein
C and S and APC (activated protein C) resistance.
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